{"id":"NCT00308685","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics","officialTitle":"Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI (PROAIRâ„¢ HFA (Albuterol Sulfate) Breath Actuated Inhalation Aerosol) in Pediatric Asthmatics","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06-10","primaryCompletion":"2006-12-04","completion":"2006-12-04","firstPosted":"2006-03-30","resultsPosted":"2022-02-24","lastUpdate":"2022-04-01"},"enrollment":95,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Albuterol","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Albuterol-HFA-BAI","type":"EXPERIMENTAL"},{"label":"Placebo-HFA-BAI","type":"PLACEBO_COMPARATOR"}],"summary":"This study is designed to evaluate the repeat-dose safety and effectiveness of a bronchodilator inhaler relative to placebo (inactive drug inhaler) in children aged 4-11 years with asthma. The dosing period lasts three weeks and starts following a three-week run-in period.","primaryOutcome":{"measure":"Maximum Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Observed up to 2 Hours Following Completion of Dosing (FEV1max%0-2) at Day 22","timeFrame":"Baseline (Predose at Day 22), 2 hours postdose at Day 22","effectByArm":[{"arm":"Albuterol-HFA-BAI","deltaMin":13.807,"sd":0.954},{"arm":"Placebo-HFA-BAI","deltaMin":8.644,"sd":1.044}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0002"}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":14,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":[]}}